SEARCH

SEARCH BY CITATION

References

  • 1
    Khorana AA. Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost 2003; 1: 24635.
  • 2
    Sampson MT, Kakkar AK. Coagulation proteases and human cancer. Biochem Soc Trans 2002; 30: 2017.
  • 3
    Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003; 124(3 Suppl.):58S68S.
  • 4
    Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003; 72: 4352.
  • 5
    Palumbo JS, Talmage KE, Liu H, La Jeunesse CM, Witte DP, Degen JL. Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency. Blood 2003; 102: 281927.
  • 6
    Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002; 62: 696672.
  • 7
    Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 33029.
  • 8
    Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 17885.
  • 9
    Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, Sottile A, Naldini L, Comoglio PM. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434: 396400.
  • 10
    Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105: 173441.
  • 11
    Bobek V, Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004; 58: 2139.
  • 12
    Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003; 23: 21105.
  • 13
    Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98: 33527.
  • 14
    Goerner A. The influence of anticlotting agents on transplantation and growth of tumor tissue. J Lab Clin Med 1931; 16: 36972.
  • 15
    Elias EG, Shukla SK, Mink IB. Heparin and chemotherapy in the management of inoperable lung carcinoma. Cancer 1975; 36: 12936.
  • 16
    Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96: 5615.
  • 17
    Kohanna FH, Sweeney J, Hussey S, Zacharski LR, Salzman EW. Effect of perioperative low-dose heparin administration on the course of colon cancer. Surgery 1983; 93: 4338.
  • 18
    LeBeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. ‘Petites Cellules’ Group. Cancer 1994; 74: 3845.
  • 19
    Fielding LP, Hittinger R, Grace RH, Fry JS. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992; 340: 5026.
  • 20
    Wereldsma JC, Bruggink ED, Meijer WS, Roukema JA, Van Putten WL. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer 1990; 65: 42532.
  • 21
    Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell Jr CJ, Forcier RJ, Edwards R, Headley E, Kim SH, O'Donnell JR, O'Dell R, Tornyos K, Kwaan HC. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 1981; 245: 8315.
  • 22
    Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, Skarin A, Kopel S, Holland JF, Comis RL. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 9931002.
  • 23
    Maurer LH, Herndon JE, Hollis DR, Aisner J, Carey RW, Skarin AT, Perry MC, Eaton WL, Zacharski LL, Hammond S, Green MR. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997; 15: 337887.
  • 24
    Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 8869.
  • 25
    Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell Jr CJ, Forcier RJ, Edwards RL, Headley E, Kim SH, O'Donnell JF. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984; 53: 204652.
  • 26
    Michaels L. Cancer incidence and mortality in patients having anticoagulant therapy. Lancet 1964; 22: 8325..
  • 27
    Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 1995; 155: 6017.
  • 28
    Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 26977.
  • 29
    Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 8009.
  • 30
    Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999; 82: 94752.
  • 31
    Conti S, Guercini F, Iorio A. Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months. Pathophysiol Haemost Thromb 2003; 33: 197201.
  • 32
    Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 6924.
  • 33
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 112.
  • 34
    Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002; 359: 6148.
  • 35
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 36
    Altman DG, Deeks JJ, Sackett DL. Odds ratios should be avoided when events are common. Br Med J 1998; 317: 1318.
  • 37
    Deeks JJ, Altman DG, Dooley G, Sackett DL. Choosing an appropriate dichotomous effect measure for meta-analysis: empirical evidence of the appropriateness of the odds ratio and relative risk. Control Clin Trials 1997; 18: 84S5S.
  • 38
    Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002; 21: 1575600.
  • 39
    Baker SG, Kramer BS. Randomized trials, generalizability, and meta-analysis: graphical insights for binary outcomes. BMC Med Res Methodol 2003; 3: 10.
  • 40
    Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 10129.
  • 41
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 153958.
  • 42
    Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 281534.
  • 43
    Messori A, Rampazzo R. Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer. Comput Methods Programs Biomed 1993; 40: 2617.
  • 44
    Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 126671.
  • 45
    Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RCN. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 19448.
  • 46
    Klerk CPW, Smorenburg SM, Otten HM, Lensing AWA, Prins MH, Piovella F, Prandoni P, Bos MMEM, Richel DJ, Van Tienhoven G, Buller HR. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 21305.
  • 47
    Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006; 81: 75867.
  • 48
    Von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000; 16: 81524.
  • 49
    Lee AYY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 21239.
  • 50
    Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, Nielsen JD, Horn A, Mohn AC, Somod L, Olsen B, Pilsgaard B, Harvald T. Prolonged thromboprophylaxis with dalteparin may improve survival in patients operated on for abdominal cancer. J Thromb Haemost 2005; 3(Suppl. 1):P2187 (Abstract).
  • 51
    Messori A. Current controversies in the application of meta-analysis (with special reference to oncological treatments). Pharm World Sci 1997; 19: 1528.
  • 52
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, for the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Eng J Med 2003; 349: 14653.
  • 53
    Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, Nielsen JD, Horn A, Mohn AC, Somod L, Olsen B. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4: 238490.
  • 54
    Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 106272.
  • 55
    Haas SK, Kakkar AK, Kemkes-Matthes B, Freund M, Gatzemeier U, Heilmann L, Von Tempelhoff GF, Brom J, Weidinger G. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer – Results of the TOPIC Studies. J Thromb Haemost 2005; 3(Suppl. 1):OR059 (Abstract).
  • 56
    Moher D, Schultz KF, Altman DG. The Consort Statement: revised recommendation for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 11914.